Bliss GVS Pharma Ltd - 506197 - Corporate Action-Board approves Dividend
Bliss GVS Pharma Board recommended a final dividend of ₹1 per equity share for FY26. The 100% dividend on a ₹1 face value is subject to shareholder approval at the 41st AGM on July 15, 2026.
May 12 2026 22:05:00
Bliss GVS Pharma Ltd - 506197 - Board Meeting Outcome for Outcome Of Board Meeting Held On Tuesday, May 12, 2026
Bliss GVS Pharma board approved audited financial results for FY26, reporting cons. revenue of ₹846.22 cr (up 4.51% YoY) and net profit of ₹97.26 cr (up 14.33% YoY). The company recommended a final dividend of ₹1 per equity share and re-appointed BDO India Services Private Limited as internal auditor for FY27.
May 12 2026 22:05:00
Bliss GVS Pharma Limited
BLISS GVS PHARMA's board is scheduled to meet on May 12, 2026. The agenda includes considering the audited financial results for the fiscal year ended March 2026, along with a proposal for a final dividend.
May 05 2026 18:05:00
Bliss GVS Pharma Ltd - 506197 - Board Meeting Intimation for Approval Of Audited (Standalone & Consolidated) Financial Results Of The Company For The Quarter And Year Ended March 31, 2026 And Recommendation Of Final Dividend If Any, For The Year Ended March 31, 2026.
Bliss GVS Pharma's Board of Directors is scheduled to meet on May 12, 2026. The agenda includes considering and approving the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and recommending a final dividend for FY26.
May 05 2026 18:05:00
Read More